HCW Biologics wins patent allowance for HCW9302 in alopecia areata

HCW Biologics has received a notice of allowance from the US Patent and Trademark Office covering the use of its lead candidate HCW9302 to treat alopecia areata, the autoimmune condition that causes patchy hair loss. The allowance adds to a portfolio of four previously issued US patents covering HCW9302's composition, nucleic acid sequences, delivery vectors and method-of-treatment claims across multiple autoimmune indications.

The Miramar, Florida-based company holds worldwide, perpetual, royalty-free exclusive licence rights to HCW9302, which it describes as a fusion immunotherapeutic built without an antibody Fc domain. The patent estate is designed to protect the compound across all indications as HCW Biologics progresses it through clinical development.

Phase 1 data and mechanism

HCW9302 is an IL-2-based fusion protein engineered with a strong bias towards the IL-2 receptor alpha subunit. The company says this bias drives preferential expansion and activation of regulatory T cells, which in turn dampen the pro-inflammatory signalling implicated in autoimmune conditions. HCW Biologics argues this selectivity sets HCW9302 apart from native recombinant IL-2 and other IL-2-based muteins and PEGylated conjugates, which the company says often show reduced binding activity at the IL-2Rα component.

Preliminary data from the first two dose cohorts of an ongoing Phase 1 dose-escalation study in alopecia areata patients are described by the company as encouraging. At a 3 micrograms per kilogram monotherapy dose, patients showed a positive response following a single administration. The trial, registered at ClinicalTrials.gov as NCT07049328, continues to be well tolerated with no dose-limiting toxicities observed, and a full Phase 1 readout is expected in the fourth quarter of 2026.

Founder and chief executive Hing C. Wong said: "Ongoing clinical activity for alopecia areata patients continues to be encouraging. With exceptionally strong intellectual property protection in place, we are vigorously pursuing alopecia areata as our lead indication of HCW9302."

Market context and competitive landscape

Alopecia areata has attracted growing pharmaceutical attention since the JAK inhibitor class demonstrated meaningful efficacy in the condition. Eli Lilly's baricitinib and Pfizer's ritlecitinib have both received FDA approval for the indication, and several other JAK inhibitors and biologics are in various stages of development. HCW Biologics is pursuing a mechanistically distinct approach through Treg expansion rather than broad kinase inhibition, and the company contends this could translate to a more targeted immunological effect with a different tolerability profile.

The IL-2 engineering space is more broadly competitive, with companies including Nektar Therapeutics and several academic spinouts having explored selective IL-2 receptor agonism in autoimmunity and oncology. Results across the class have been mixed, which means the full Phase 1 dataset anticipated this quarter will be closely scrutinised by investors and clinicians looking for dose-response consistency and durable responses beyond a single administration.

HCW Biologics (NASDAQ: HCWB) has also entered two out-licensing agreements covering other molecules in its portfolio, suggesting a partnering-forward strategy that may extend to HCW9302 should Phase 1 data support advancing to a larger, more expensive Phase 2 programme.